Established on the diagnostics market for 30 years, Theradiag is now recognized as a key player in the development, manufacturing and marketing of innovative in-vitro diagnostic products, but also as a pioneer in Theranostics. This extensive experience in the field of diagnostics, combined with the reliability of our products and the performance of our customer service, enable us to address biologists as a high-quality partner with ISO 13 485 certifications.
With a presence in more than 30 countries through its in-vitro diagnostic activities and benefiting from buoyant growth in the field of Theranostics, Theradiag has a broad range of unique and innovative areas of expertise to provide a personalized response for each of its clients, biologists and clinicians. Theradiag is a leader in Theranostics and the monitoring of auto-immune diseases, the world’s third-greatest cause of morbidity.
Theradiag’s sales and marketing operations are organized into two main activities:
– the “Theranostics” activity, which consists exclusively of in-house products developed through internal R&D, provides a personalized medicine solution for biotherapies used for treating auto-immune diseases and cancer;
– the “In-vitro Diagnostics” activity covers in-house products and distribution products mainly in the fields of auto-immunity, allergies, infectious diseases and, more recently, oncology and molecular biology.
Theranostics, diagnostics applied to a specific therapy, give clinicians the means to control the efficacy of drugs derived from biotechnology and to personalize treatments for each patient.
Theradiag has developed and received the CE Mark for Lisa Tracker, the world’s only comprehensive range of tests for monitoring the monoclonal antibodies used in the treatment of auto-immune and inflammatory diseases. Monitoring tests for cancer treatments such as Rituximab and Bevacizumab have recently enabled the range to be expanded to oncology, and new products are currently being developed to supplement this range. Lisa Tracker has seen buoyant growth in its activity in recent years thanks to its international marketing and to the publication of numerous studies demonstrating the clinical appeal of monitoring the treatments concerned.
For the last three years, in-vitro Diagnostics, Theradiag’s historical activity, has focused on developing products that have been designed and manufactured in house and innovative distribution products (molecular biology). Theradiag has recognized expertise in the diagnosis of auto-immune diseases with its multiplex test range (Technologie Luminex®) that covers the main auto-immune diseases.
Since its IPO at the end of 2012, Theradiag’s strategic reorientation, focusing on the development of proprietary kits and notably Theranostics, has allowed the Company to increase its profitability and is the cornerstone of its future development.